Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
48
VRAI Quote, Financials, Valuation and Earnings
Last price:
$23.02
Seasonality move
:
-2.98%
Day range:
$23.12 - $23.15
52-week range:
$19.65 - $24.49
Dividend yield:
4.69%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.1K
Avg. volume:
1.6K
1-year change:
1.96%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VRAI
Virtus Real Asset Income ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VRAI
Virtus Real Asset Income ETF
|
$23.15 | -- | -- | -- | $0.39 | 4.69% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$40.24 | -- | -- | -- | $0.66 | 1.63% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$82.44 | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VRAI
Virtus Real Asset Income ETF
|
-- | 0.468 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.813 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 0.818 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VRAI
Virtus Real Asset Income ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
Virtus Real Asset Income ETF vs. Competitors
-
Which has Higher Returns VRAI or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Virtus Real Asset Income ETF's net margin of --. Virtus Real Asset Income ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRAIVirtus Real Asset Income ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About VRAI or BBC?
Virtus Real Asset Income ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Real Asset Income ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Virtus Real Asset Income ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings VRAIVirtus Real Asset Income ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is VRAI or BBC More Risky?
Virtus Real Asset Income ETF has a beta of 0.803, which suggesting that the stock is 19.733% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 0.983, suggesting its less volatile than the S&P 500 by 1.702%.
-
Which is a Better Dividend Stock VRAI or BBC?
Virtus Real Asset Income ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 4.69%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.63% to investors and pays a quarterly dividend of $0.66 per share. Virtus Real Asset Income ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAI or BBC?
Virtus Real Asset Income ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Virtus Real Asset Income ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Virtus Real Asset Income ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Real Asset Income ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAIVirtus Real Asset Income ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns VRAI or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Virtus Real Asset Income ETF's net margin of --. Virtus Real Asset Income ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VRAIVirtus Real Asset Income ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About VRAI or BBP?
Virtus Real Asset Income ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Real Asset Income ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Virtus Real Asset Income ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings VRAIVirtus Real Asset Income ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is VRAI or BBP More Risky?
Virtus Real Asset Income ETF has a beta of 0.803, which suggesting that the stock is 19.733% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.974%.
-
Which is a Better Dividend Stock VRAI or BBP?
Virtus Real Asset Income ETF has a quarterly dividend of $0.39 per share corresponding to a yield of 4.69%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus Real Asset Income ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VRAI or BBP?
Virtus Real Asset Income ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Virtus Real Asset Income ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Virtus Real Asset Income ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Real Asset Income ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VRAIVirtus Real Asset Income ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
